The left atrial substrate plays a significant role in the development of complex atrial tachycardia in patients with precapillary pulmonary hypertension

by Zdenka Fingrova, Stepan Havranek, David Ambroz, Pavel Jansa, Ales Linhart
Published 2019-06-01

The impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension - results of a retrospective clinical registry

by Pavel Jansa, David Ambroz, Jan Kuchar, Vladimir Dytrych, Jaroslav Lindner, Ales Linhart
Published 2021-06-01

The prevalence and clinical outcome of supraventricular tachycardia in different etiologies of pulmonary hypertension.

by Zdenka Fingrova, David Ambroz, Pavel Jansa, Jan Kuchar, Jaroslav Lindner, Jan Kunstyr, Michael Aschermann, Ales Linhart, Stepan Havranek
Published 2021-01-01

Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile

by Pavel Jansa, Samuel Heller, Michal Svoboda, Michal Pad’our, David Ambrož, Vladimír Dytrych, Michal Širanec, Tomáš Kovárník, Marián Felšőci, Martin Hutyra, Aleš Linhart, Jaroslav Lindner, Michael Aschermann
Published 2020-11-01

Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice

by Danica Michaličková, Pavel Jansa, Miroslava Bursová, Tomáš Hložek, Radomír Čabala, Jan Miroslav Hartinger, David Ambrož, Michael Aschermann, Jaroslav Lindner, Aleš Linhart, Ondřej Slanař, Elke H.J. Krekels
Published 2020-01-01